Continuing the discussion we had on class 1/30 on cloning. I believe that cloning hold the key to developing a plethora of medical advances, from finding cures to cancer, and to solving food issues. With cloning stem cells can be replicated, thus fewer fetuses must be used to obtain these cells. This would then result in more support, both morally and financially. With this funding and a higher interest from the general public, medical advances are bound to occur. Then cloning can be used to create genetically engineered food, which then can be used to increase crop yields, even with the changes in environment which are occurring. If a plant is developed which can endure the blistering heat and lack of water in
Thursday, January 31, 2008
Cloning
Wednesday, January 30, 2008
Tuesday, January 29, 2008
And yes, if amateur entrepreneurs can survive and even come to dominate the American marketplace, then the governments of developing countries could successfully improve their economies and states of existence. But in order to do so, all other developed countries need to agree not to invade the countries; they need to let them reconstruct themselves and their own cultures without the interference or influence of multiple other countries, and with however much time they may need.
2
Monday, January 28, 2008
Pro Humanitate
Pro Humanitate
Pro Humanitate
Thursday, January 24, 2008
Machines
blog 1
Are we just machines?
Tuesday, January 22, 2008
Videos
Thursday, May 10, 2007
An Award Winning Class
After the first two weeks of class, I was asking, “What did I get myself into?” In the same period, three of our original fifteen students had dropped the class, at least one of whom could not believe how hard it was.
Yet, despite the initially surprisingly large workload, I stayed. I was intrigued. “Harnessing Life’s Molecular Machines: From AIDS tests to Hydrogen Cars” simply had me hooked. Yet even with this interesting, and complicated, title, I never expected the learning and experience opportunities that were presented by this class.
The class had a wide variety of components that were all crucial to the learning process. From field trips to guest speakers, from in-class discussions to blogs, this seminar was a class such as I have never taken at
From the first day, with our class-wide viewing of professor Macosko’s favorite animated film (so far) by XVIVO, I knew that the class would be hard, complicated, interesting, and fun. It seemed as if it was tailored to my exact specifications. Molecular machines were a field of biology that I had little experience with, and entrepreneurship was a field I had no experience with. Yet now, I feel adept with both.
To an outsider coming into the class, it might seem as if we were involved in a high level biophysics course. We even had an upper class textbook as a PDF file on our laptops. Yet here we were, a group of fourteen freshmen and one sophomore, embarking on a journey of epically miniscule proportions.
Our various discussions kept the class engaged and interesting. Our first discussion was concerned with answering the question “Are humans just machines?” I adamantly argued that they were, playing the devil’s advocate. This later earned my group the affectionate name of “The Machines.” I am still not sure if anyone knows that I think there are more components to humanity that just the sum of our parts, but I did not have an adequate explanation as to why at the time, and it appeared as if no one else did either.
Our next discussion questioned the implications of Grey and Green Goo. The general idea involved a concept invented by a certain Eric Drexler, author of 1986 book Engines of Creation. Grey goo is a term describing an apocalyptic scenario in which the nanotechnology we, as future scientists, have the potential to create takes over the world. The concept of green goo extends this idea to bionanotechnology, which my have equally scary implactions. Perhaps we will invent, discover, and create to the point where we can no longer control our own technology, and it will destroy us in the end. So warns Eric Drexler.
After this, we had a long break filled with hard work, guest speakers and field trips until our next discussion on philosophical and technological biases in science. We pointed out how technical biases remain due to financial issues, while philosophical biases are deeply set in the beliefs of the people, and are therefore at least equally difficult to dislodge. We went on to discuss how these biases affect thoughts on global warming, and extended these ideas to the field of scientific research as a whole. Essentially, we said that it is financially easier to sit back and do nothing about global warming in the short run, and that people are so comfortable in their lives of luxuries, that they do not even recognize them as luxurious anymore, and therefore are unwilling to sacrifice for the not-so-distant future. Personally, I found this discussion the most important of all, since it has potential to have serious effects on our generation, and we will be the first who will have to take action against global warming.
Throughout the semester, we had several guest speakers. The first, Dr. Ray Kuhn, came and discussed his venture with a diagnostic test for bacteria on catfish. Because the fishery industry in the southeast is a multi-million dollar market, Dr. Kuhn’s test can save these fisheries a lot of money, while making him and his students a lot of money. His idea depends on maintaining the secrecy of how his test works, and he can do this with patents and copyrights. His company is likely to gross millions in profits within the next five years. Intriguingly, it started the same way our “BioBotz Inc.” company is starting, with a faculty advisor and a group of devoted young students.
The next speaker, Walter Bradley, explained how he could use the coconut market in developing countries to jumpstart the economies of failing communities. He explained how far-reaching coconut growth could be, and what the market could extend to. He took a philosophy reminiscent of a Native American, in which he used every single part of the coconut to create goods. He used the pulp for food and to create coconut butter, the milk as a drink and a fuel, the husk as a material to press into particle board, and the shell as a material to be used similar to plastics or ceramics. He planned to teach communities how to create all these things, and then give them the means to self sustain their villages.
The final guest speaker, Graham Johnson, was a medical animator that showed us how he animated and illustrated molecular machines for biology and medical texts. His background in science and talent for art allow him to occupy a very small niche, and his art was accurate and astonishing. It was intriguing that such advanced animation could be used to so accurately portray molecular machines.
Field trips made up a substantial portion of the course as well. The first, our trip to the
Our second field trip, this one to Professor Macosko’s laboratory, illumined the actual lab technology required to research molecular machines, and exactly how difficult it is. We heard about how cloning of bacteria simplifies the creation of proteins immensely, and how beads and fluorescence can track the progress of motor proteins.
Our third field trip went downtown to hear Peter Perret discuss auditory learning in children. He professed that a correlation between music and learning existed and showed convincing numbers supporting this idea from research conducted in
I had a much more personal and individual field trip to Out of Our Minds Studios, an animation company that had an impressive number of awards on the mantle upon entering their office in downtown
Another major component of the class was student presentations. Each student was required to present on three different molecular machines throughout the semester. I began with a presentation on myosin and its interaction with acting. Myosin is a molecular walker that drives muscle contraction and tows organelles inside the cell. My next presentation was on an enzyme called glucose oxidase, used in almost all diabetes glucose meters. My final presentation concerned the business plan my group mates and I wrote in order to receive a grant from the Center for Entrepreneurship. We explained our general thought processes and methods, and later found out that our grant proposal received almost the full amount of the $1000 goal.
Despite all these intriguing and fun aspects of the course, by far the most interesting has been the development of BioBotz Inc. BioBotz Inc. is a budding corporation thought up by Professor Macosko, and left to my partners and I to get on its feet. Beginning with applying for a $1000 grant for initial development, the company hopes to use larger grants and investors to create a children’s book, television cartoon, and video game based on the inner workings of the cell and, more importantly, a molecular machine called kinesin. Kinesin is a tiny machine that tows bodies that are many times its size from place to place throughout the cell. Our long term goals are to get a larger television studio to take over development of the show, and then to market our television show, video game, storybooks, and associated products such as action figures and stuffed toys. We want to combine entertainment with education in order to allow the country’s future scientists to explore the interior of the cell in a fun, interactive way.
The creation of this company has been my personal project, far beyond the capacities of the class. Originally, it began with Professor Macosko, my two group partners, and I creating the grant proposal. Now, we have two artists, eight freshmen from the class, a children’s book researcher from the art department, Professor Macosko, and Professor Varner from the entrepreneurship department, involved. Its development has resulted in the foundation of an entrepreneurship class devoted entirely to continuing to develop the company that almost all the freshmen involved are taking this fall. The company is already beginning to grow. With our initial grant, we can begin development of our children’s book and storyboard over the summer, and hopefully we can use market research at schools to validate our idea and convince large grant holders to give us more money. I hope that as we develop, we can teach, entertain, and make money, all at the same time.
It appears as if no one else has come up with an idea that takes the story inside the cell. We hope that our originality and appeal to education will make our product unique and reputable. We also hope that it is entertaining enough to become main stream, in order to make some money. I think that we looked at these molecular machines at the perfect time. Everything in the world, in technology, has entered a trend of smaller. There is now an iPod that is smaller than one square inch, and is clipped to whatever clothes the consumer is wearing. Hopefully, people will retain interest in a world growing ever-smaller.
Overall, I have never been involved with such a class. Through discussion, presentation, argumentation, research, writing, traveling, and proposing, I have learned more about entrepreneurship and molecular machines and their applications than I could have in any other setting. It is no wonder that the class won the Entrepreneurship Award for Course Development. Taking an innovative route, using unconventional methods, yet including the necessary parts of a first year seminar, this class deserved the award more than any other. I pity the few that dropped the class, I am proud to have taken it, and cannot wait to apply what I have learned to the development of BioBotz with my classmates. I look forward to continuing its development and, hopefully, making the big bucks.
Tuesday, May 1, 2007
Guest Speaker
Animation Speaker
Monday, April 30, 2007
Guest Speaker
Animaton Talk
Awesome animations
Sunday, April 29, 2007
animator
Wednesday, April 18, 2007
Global Warming (the science, the economics)
Nanotechnology kills cancer
Jane Lee
FYS: Biotechnology and Molecular Machines
4/18/2007
Nanotechnology kills cancer
In 2003, Naomi Halas goes for the gold. The precious metal gold has uses that are expanding beyond jewelry making and is now highly valued among oncologists and patients with cancer. She discovered that gold can be used in a potential treatment for cancer. Naomi Halas’s creation of the brilliant brilliance tools is one of the many novel technologies that utilizes both nanotechnology and bionanotechnology in the detection and treatment of cancer. While nanotechnology and bionanotechnology are completely different fields of research, in the treatment of cancer, “grey-goo” (referring to nanotechnology) and “green-goo” (bionanotechnology) have formed a lethal combination. Within the last five years, nanotubes, nanoshells, nanoparticles, and nanocomplexes are tools that have been created and have been combined with the biological identification system, known as antibodies. By considering three technologies that utilize nanotechnology and biological markers, it is obvious that these nanotechnologies have been advantageous in the fight against cancer and can be the future in cancer research. Based on different methods, each of these tools has the potential to radically improve the methods of detecting and destroying cancer cells.
There has been a search for finding new optical material for drug delivery and biological markers. Meanwhile, Halas who previously worked with nanoparticles to control electromagnetic waves was referred to Jennifer West to find a biological marker by finding particles that would radiate light. Halas decided to go an alternate route with gold nanoshells instead of carbon nanotubes because of it can more precisely control waves of light. Gold nanoshells do not trigger immune defenses; therefore the injection of the nanoshells into the body would not cause any severe side-effects. These gold nanoshells were found to accumulate in cancer cells because of the hyperpermeability of the vessels. In other words, because tumors are leaky large molecules, such as gold nanoshells, that could not normally diffuse through vessels can penetrate tumors. The accumulation of gold nanoshells at these sites would allow researchers to detect cancer from a reflection of waves from these microscopic gold shells.
When Halas and West became partners, they discovered more than a way to detect cancer from the buildup of gold nanoshells at these leaky sites. After the gold accumulated to tumors, an invisible infrared laser light was shined on the skin. At a light wave frequency that was high enough, the gold nanoshells were found to destroy cancer. This was due to the gold’s ability to superheat when a light frequency hits, while still remaining at a harmless frequency so that the light emitted from the shell does not kill nearby healthy cells. This process is similar to the intensification and focusing of a light shining through a magnifying glass.
Although this showed promising results for the destruction of tumors with leaky sites, but there were flaws that needed to be modified to ensure that the gold nanoshells traveled only to tumor sites. Other than the leaky vessels that surround tumors, cancer is identified by specific protein receptors. Depending on the type of cancer, many cells display ratios of different proteins in the cell membrane which acts as a marker to identify the cell as a cancer cell. With this knowledge and based on other successful nanotechnologies that utilized antibodies, the gold nanoshells were modified so that antibodies attached to the shell to allow more precise delivery. Since gold nanoshells do no trigger immune response, they have the potential to travel throughout the blood. Gold nanoshells can target and kill cancer cells that have metastasized without leaving behind a toxic trail.
Naomi Halas discovery of gold nanoshells for the treatment of cancer is actually a more radical nanotechnology because her unconventional use of gold instead of carbon, which is the material most often exploited in nanotechnology. The first major nanotechnology that researchers studied was carbon nanotubes. Because of its diverse properties, carbon nanotubes have been used in a variety of applications. Carbon nanotubes 20 to 100 nanometers long is small enough to easily permeate through any cell membrane and into cells which is more useful than relying on the leaky vessels of tumor cells. Because of its ability to penetrate through membranes, carbon nanotubes have been used to deliver drugs into cells. In order to target specifically cancer cells, the carbon nanotubes require special identification.
Halas’s modification of gold nanotubes to specifically target certain cancer cells was based on the technology created by Dr. Balaji Panchapakesan, who coated a single walled carbon nanotube with monoclonal antibodies. Antibodies, the special identification system, only allow for specific access into the cancer cells. Nanotubes with monoclonal antibodies were found to detect breast cancer, and later modified into what are being called “nanobombs” to fight the growth of reoccurring cancer cells.
Nanobombs travel through the blood, find and target cancer cells. Antibodies are first attached to carbon nanotube wires to create nanosensors. Panchapakesan discovered that the binding of an antibody to its target molecule creates an electric current, and that this current is proportional to the number of receptors on the cell and number of antibodies on the carbon nanotube. By detecting the change in electric current, the antibodies attached to the carbon nanotubes can detect cancers if there is the presence of certain target molecules, “markers,” which are found on exclusively on certain cancer cells. Panchapakesan discovered that these electric currents, with the right modifications, such as the right number of antibodies, waves can actually blow apart the cancer cells it enters, acting as nanoscale bombs with shockwaves that can kill the cancer cells and blood vessels around these cancerous cells. It does this with the absorption of near-infrared light, which is harmless under normal cirucumstances. Since the carbon nanotubes only enter the cancer cells for which it has antibodies attached to, healthy cells are not affected.
Antibodies have also been incorporated into a system of nanoparticles that holds and releases drugs when necessary. This nanotechnology has been successfully created to safetly contain and administer chemical assassins. When the nanoparticle penetrates a cancer cell, it can release chemicals such as hormones, cell-killing peptides, or anticancer drugs which have the potential of destroying primary and cancer cells that have metastasized. As targeting delivery systems, the drugs are specified to the type of cancer being detected or treated. This technology delivers drugs in small doses that cannot penetrate cell membranes but are essential for the cell’s function. These particles can also be programmed to slow-release in treatments that require this type of technology. Similarly, nanoparticles made up of liposomes have been called nanocomplexes. Dr. James Baker discovered these nanocomplexes as man-made nanoscale machines with tiny tendrils that could be engineered to battle specific cancers. Baker worked with chemist Donald Tomalia who created dendrimers. From this teamwork emerged nanocomplexes, which are covered in antibodies, have been used with gene therapy and have proven to be another means to cancer detection and therapy. Nanocomplexes work similar to viruses. They can splice part of the genome without the unreliability of viral vectors. Using the gene that triggers apoptosis, the nanocomplexes turn the cancer cell against itself.
Scientists have looked toward other solutions to fight cancer. Nanotechnologies and bionanotechnology is the key to both detecting and fighting cancer. Because of their miniscule size, nanoparticles, nanotubes, and nanoshells are able to enter cells. Even despite their small size, nanoparticles, shells, and tubes are able to cause damage. The research available shows promise of a shorter diagnoses period, cut down to minutes instead of days. The therapies for killing tumors both primary and metastatic are targeted and nontoxic. Therefore healthy cells are not damaged as they are in therapies available today. Additional advantages are the self destruct of carbon nanotubes when it kills the cancer cells and the self-destruction of cancer cells. Macrophages can clean up the shells so that there is not a buildup of carbon material which can potentially cause problems including blockage in blood vessels and kidneys. These therapies provides fewer side effects than the available treatments such as chemotherapy, which nonspecifically kills normal cells in addition to cancer cells. Halas, Panchapekan, and Baker created nanotechnologies that can destroy specific targeted cancer cells by use of antibodies and properties of the shells and light or gene therapy. These technology to destroy cancer can not only detect cancer within a few minutes instead of days, but can destroy cancer without the toxic effect of current treatments.
References
http://www.pbs.org/wgbh/nova/sciencenow/3209/03.html
http://www.ece.rice.edu/~halas/
http://nano.cancer.gov/news_center/nanotech_news_2006-01-17d.asp
http://www.wired.com/medtech/health/news/2005/07/68195?currentPage=2
Monday, April 16, 2007
Global Warming
Current energy resources like oil are an enviornmental hazard. Huge oil exporters like Nigeria see their people suffer from damage the "black gold" has inflicted on the country's once fertile shorline. Farming is nearly impossible in the country's Niger Delta region. Similary, fishermen from the region find it difficult to feed themselves; all the fish have died from water pollution resulting from oil spills.
We must understand that in preventing global warming we will better the world. It is impposible to deny that cleaner and more progressive technologies and energy resources will enhance our lifestyles.
Thursday, April 12, 2007
Global Warming
Global Warming
Wednesday, April 11, 2007
Global Warming
Global Warming
Tuesday, April 10, 2007
Global Warming
Monday, April 2, 2007
Terminator Technology
Thursday, March 29, 2007
Liposomes and Cancer Therapy
3/8/07
FYS
Liposomes: Packaging the Future of Cancer Treatments
Accounting for nearly one quarter of all deaths in the United States, cancer is a looming threat to people across the world. However, thanks to continued research in the development of more effective cancer fighting treatments, the death rates of cancer victims have significantly decreased from 1950, to present. Fighting cancer relies on three main technologies: chemotherapy, surgery, and radiation. Chemotherapy works via the transfer of cytotoxic drugs to specific locations in the body. The transfer must occur without interaction with healthy cells as the drugs circulate in the bloodstream. In addition, the drug must avoid destruction by the immune system, which recruits phagocytes such as macrophages to destroy foreign substances in the bloods stream. Nanotech biomimetics offers a wide range of utilities to overcome these complications by taking ideas from nature and incorporating them into technology. Liposomes are natural packaging devices flowing through the bloodstream that have been harnessed as drug dispensers for cancer treatments. Its design as well as functional capabilities allow it to deliver cancer treatments to target areas without harming healthy cells and without triggering the immune system.
Liposomes were discovered in 1961, by Alec Bangham at Cambridge University and were first used as drug delivery systems 30 years later (Tianshun). The structure of the liposome enables it to increase the potency while at the same time reducing the toxicity of the drugs it carries. Liposomes exhibit self organization that is triggered when certain phospholipids are exposed to an aqueous environment and utilize the hydrophobic effect to form a spherical lipid bilayer with the hydrophilic phospholipid heads facing out. The aqueous solution that is trapped inside the bilayer provides a carrying space for drugs that is sequestered from the aqueous outer environment. The formed vesicle may range in size from 50 to 200 nm in diameter and may be encased by one layer of phospholipids such as in a unilamellar liposome, or may have several layers that resemble an onion in a multilamellar liposome (Lian).
Although the synthesis of liposomes appears simplistic, serious complications are yet to be resolved with the development of a low cost method of mass production. The success of liposomes as a cheap medical device depends upon the formation of liposomes with adequate drug entrapment capability, appropriate size, relative stability, and drug release capability. Scientists use sources of energy such as sound and heat to agitate phospholipids in an aqueous solution into vesicle form, but they are unable to control the size and structure of the final product. The use of energy stimulated vesicle formation risks denaturing the drugs that are in the aqueous solution that will be enclosed inside the liposome. One of the main complications with liposome use in the human body is that one of the first steps in vesicle formation is to dissolve the lipids in a volatile organic solvent such as methanol. These solvents are often toxic and can affect the inner cargo, destabilize the lipid membrane, or remain as Organic Volatile Impurities (OVI’s) in the lipid membrane where they will later intoxicate healthy cells in the body (Mozafari).
In the medical world, drug companies utilize liposomes as an effective means of drug delivery. Water soluble drugs, including cancer drugs, are inserted in the aqueous compartment inside the phospholipid outer membrane. The liposomes are then introduced into the bloodstream, and the hydrophobicity of the outer bilayer keeps the drugs separated from the blood until the liposomes reach the targeted cells. This process is especially adept for cancer treatments because the phospholipid bilayer keeps toxic drugs from affecting healthy cells and can be modified to “target” cells like macrophages and tumor cells.
In order for drugs to be transferred into a cell, the liposome must interact with the target cell. Interaction occurs through several methods. The liposome may simply bump into the target cell, forming a weak bond with the cell membrane that allows drugs to diffuse directly into the cytoplasm of the cell. Other cells engulf the liposomes with the cell membrane through endocytosis. Once inside, the liposome fuses with a lysosome that contains phospholipases that degrade the liposome and release the drugs. Ligands called opsins are often appended to liposomes and instigate endocytosis by directing the liposome to the target cell. In addition, alteration of the pH inside the water compartment of the liposome creates a charge on the dissolved drug. Once the liposome is engulfed, the liposome will fuse with the organelle encasement and release the drug particles into the cytoplasm (Gregoriadis).
Cancer therapy utilizes specific characteristics of tumor cells in the transfer of cytotoxic drugs from the liposome to the target cells. Healthy blood vessels have an endothelial wall with tightly packed endothelial cells that prevent large molecules in the blood from leaking out of the vessel. The epithelial walls of vessels in tumor sites exhibit EPR, or enhanced permeability and Retention. Due to gaps in the epithelial wall, liposomes that are 400 nm or less can leak into the tumors. Tumors and cancerous lesions are therefore prime targets for liposome drug administration.
The main targets of cancer fighting drugs are TAMS, or tumor associated macrophages. Macrophages are cells in the immune system that originate from white blood cells called monocytes. They function in the immune system as phagocytes, meaning they engulf dangerous and potentially harmful material inside the cell such as pathogens. Instead of aiding in immunity like normal macrophages, TAMS produce chemokines and cytokines that promote tumor growth and metastasis. Scientists hypothesized that they could use liposomes to transfer a cytotoxic drug to the TAMS, which would in turn stop the progression of the tumor.
Consequently, the cytotoxic drug of choice was bisphosphonate clodronate, or Clodrolip. Encapsulated into unilamellar liposomes, this drug is commonly used for its ability to destroy TAMS and therefore cease the production of chemokines and cytokines. Tests performed on mice showed that the liposome administered Clodrolip inhibited tumor growth in 75% to 92% of the cases. Reduction of growth rate of tumor was significant up to nine days after treatment. Clodrolip is one example of an effective drug transferred by liposomes that has can inhibit hard tumor growth and metastasis.
Another liposome-packaged cancer treatment is NOAC. It is cheaply synthesized in lyophilized, or freeze dried liposome form and has high proprietary support for research. The lyophilized package is mass produced in highly purified form in four steps, using the cheap ribonucleotide uradine (“Liposomes: general properties). Through liposome delivery, NOAC has been shown to inhibit growth in breast, prostate, and lung tumors as well as fight leukemia. Research on freshly biopsized cancer cells in ovarian and mammary carcinomas showed NOAC to by highly cytotoxic to the tumor cells. It also showed success in inhibiting growth in melanoma and tumors that exhibited resistance to multiple drugs. Scientists tested NOAC on freshly biopsized human tumors at concentrations from 10 to 100 micromolar. At these concentrations mammary, lung, and ovarian carcinomas as well as non-Hodgkin lymphomas were highly inhibited (Schwendener). Liposomes play an active role in the administration of NOAC, as well as other notable cancer fighting drugs on the market such as Doxorubicin (Doxil) and Daunorubicin (Daunoxome).
Finally, scientists optimize the performance of liposomes through the addition of anti-tumor antibodies to the outer membrane of the liposome, creating what are known as immunoliposomes. Immunoliposomes target the tumor cells and make drug transfer more efficient. In addition, immunoliposomes can be sterically stabilized, meaning they are less likely to be filtered out of the bloodstream by the immune system and are able to circulate for a longer time. This is accomplished through the attachment of hydrophilic polymers or glycolipids to the liposome membrane. The modified liposomes act like targets that fit into receptors on target cells (“Liposomes: general properties”). The added target fragments do not increase the effect of the drug, but allow the drug to reach the target cells faster and circulate longer.
A special case study was performed by scientists on the effects of attaching single chain antibody fragments to liposomes containing cancer fighting drugs. They linked the antibody fragments to liposomes and radioactively labeled them so they could monitor their locations through fluorescence. A control group containing unmodified liposomes and the experimental group of modified liposomes were introduced into the bloodstream of tumor stricken rats at the same time. Two hours after injection, scientists found that the modified liposomes accumulated in tumors in concentrations two to three times that of the unmodified liposomes. However, after an extended period of time, the concentrations evened out. This proved that attaching “target” fragments to liposomes expedited the treatment by targeting the tumor cells. As expected, the drugs inhibited tumor growth in the rats. Overall, the experiment proved the efficiency of drug delivery with target lipsomes versus that of unmodified liposomes.
Liposomes are cheap, effective means of drug transportation in the medical field. They are the key to cancer therapy and the delivery of cytotoxic drugs that would otherwise ravage healthy cells. The intricate packaging system, harnessed from the ideas of nanotech biomimetics, is now the hopeful future of cancer research. Liposomes are simply a nano-scale machine harnessed within the human body to manipulate the placement of drugs that may one day defeat the onslaught of cancer.
Tuesday, March 27, 2007
ADDL Paper
Ashley Edwards
FYS Molecular Machines
ADDLs
Amyloid beta-derived diffusible ligands, ADDLs, bind in groups to neurons in the brain and are thought to cause Alzheimer’s disease. If ADDLs could be stopped from binding to the neurons, then the progression of Alzheimer’s disease could possibly be slowed down or even stopped completely. Acumen, a pharmaceuticals company, has already begun research to try and determine just how ADDLs can be stopped from making damaging clusters in the brain. Since aptamers can be selected to bind to certain things, if they could be selected to bind to the neurons and proteins that ADDLs bind to, then they would be very effective at helping stop the spread of Alzheimer’s in the brain.
Merck, a company that has already entered into a contract with Archemix, the leading company in aptamer research, has promised 48 million dollars for research into ADDLs and will give another 48 million dollars if a vaccine is developed. Merck and Acumen, the leading company in ADDL research, have entered into a contract where Merck will have exclusive rights to Acumen’s ADDL technology. Acumen is working on an assembly blocker and a binding inhibitor to stop the ADDL from initiating Alzheimer’s disease. The assembly blocker would work to stop the production of the oligomers, so that the ADDL would never be able to form. As this is a protein-protein interaction, it would be very difficult to target, but aptamers again look like a promising choice as a target molecule. The binding inhibitors would prohibit the ADDLs from binding to the neurons. This would work by either having a molecule bind to the ADDL where it would bind to the neuron, or having a molecule bind to the neuron. Again, aptamers might prove useful as a target molecule for either of these options. Acumen has not discussed using aptamers in either of their projects, but that does not mean that it isn’t a viable option. Acumen has discussed their selection process for molecules that might potentially bind to the ADDLs, but they have not yet released what molecules they are using in the selection process. Similar to SELEX, their selection process consists of placing a large quantity of small molecules into solutions with different ADDLs to determine whether or not they bind. They also test them in vitro to make sure the molecules would not be potentially toxic. Acumen would also then test whether or not those ADDLs would bind to the neurons or not, to make sure that the molecule was binding in the correct place. They have not yet released their plans for the selection of molecules to bind to the receptor sites on the neurons.
Both Acumen and Merck seem to be at the forefront of medical technology, and if successful, could make Alzheimer’s disease obsolete in a few years. Merck has seen some hardships in the past few years, with a withdrawal of Vioxx, an arthritis painkiller, and multiple lawsuits that claimed Merck did not properly warn the public about the risk of heart attack as a side effect of Vioxx. As a result, their stock went down starting around October of 2003, and has never fully recovered, although it is well on its way to surpassing where it was before the crash. Both Acumen and Merck would be excellent companies to invest in because a cure for Alzheimer’s disease would have profound effects on society and would generate a lot of revenue. Merck seems to be very involved in other risky, high-tech, medicine research that could pay off big in the next ten years or so. Archemix, the aptamer research company, has also entered into a contract with Merck. The main focus of their agreement is research into targeting cancerous cells using aptamers and if this is successful, then obviously both Merck and Archemix will begin making millions. All three of these companies would be great investments, because although risky, they have enormous pay-offs if successful. These new technologies will most likely provide the basis by which almost all diseases will be treated within the next ten to twenty years, and getting aboard now would be wise. Before investing, however, it is always smart to look at what exactly the companies are working on.
ADDLs are sticky, insoluble proteins that can clump together in messy groups in the brain and cause large build-ups of sticky fibers that attach themselves to neurons. Amyloid beta is a peptide made up of amino acids that forms after sequential cleavage of the amyloid precursor protein (APP) by the β- and γ-secretases. APP is a transmembrane glycoprotein, which means it is made up of a protein and a carbohydrate. The amyloid beta protein can then go through proteolytic processing, which would cause the digestion of proteins by enzymes. The exact proteolytic processes that cause ADDL to form are most likely the mutation of Ab peptides that have 40 peptides into ones with 42 peptides. This mutated form can then bind to neurons and cause Alzheimer’s and occasionally the death of the neuron. By attaching to the neuron, the ADDLs disrupt the normal signaling and cause the memory problems and dementia in Alzheimer’s disease.
The tau protein, which is a microtubule-associated protein normally found in the brain, has also been thought of as a cause of Alzheimer’s. Like ADDLs, it is found in high concentrations in the brain of patients with Alzheimer’s because it occasionally goes through hyperphosphorylation that causes large groups of tangled tau proteins and damages neurons. However, Jan Naslund, Ph.D., from
ADDLs are thought to interfere with long-term potentiation as an effect of binding to the neurons. Long-term potentiation is involved in spatial memory and is essential to learning. The ADDLs are also most likely to affect the hippocampus, and therefore affect the spatial navigation. Because the ADDLs affect these two things, researchers believe that they are the cause of synaptic memory formation loss and eventually lead to the dementia in Alzheimer’s patients. High concentrations of ADDLs have also been tied to the destruction of nerve cells that never regenerate, causing the slow deterioration. Below is a figure depicting the amyloid beta clumps that interfere with the neuron activity. If the clump grows large enough, it can cause the death of the nerve cells. The oligomers are also shown causing damage to a neuron, and those oligomers would most likely eventually turn into a clump of amyloid beta which would further damage the neurons. A clump of tau proteins is also shown in this diagram.
In order to stop the amyloid beta from forming ADDL, many solutions have been proposed. β- or γ-secretase inhibitors would stop the cleavage of APP and therefore would stop the production of amyloid beta and its mutations. Acumen is also working on inhibiting the production of oligomers so that the amyloid beta clumps would never form. Aptamers could possibly be selected to bind to whatever it is that ADDLs bind to, but at this point it is unclear if there is a specific site they bind to on the neurons, or if large clumps just happen to form sporadically. An immune attack on the ADDLs has been discussed, and since aptamers are also used as escorts, they could carry ADDL destroyers and could be selected to bind to the ADDL fibers.
ADDLs are almost universally agreed upon by scientists to play some role in the development of Alzheimer’s disease. Although there is dispute about whether the tau protein plays a larger role than the ADDLs, hopefully the scientists at
Works Cited
"Acumen Pharmeceuticals." 2006. 6 Mar. 2007
"ADDL Research Provides Vaccine Hope." About.Com. 29 Sept. 2006. 7 Mar. 2007
"Amyloid Beta." Wikipedia. 8 Feb. 2007. 5 Mar. 2007
"Amyloid Beta-Peptide Levels Associated with Early Dementia." 21 Mar. 2000. Doctor's Guide Publishing Limited. 5 Mar. 2007
"Amyloid Beta: a Stealth Protein That Destroys Thoughts and Memories in Alzheimer’s Disease." 2007. The J. David Gladstone Institutes. 5 Mar. 2007
Klein, William L. "Molecular Basis of Alzheimer's Disease; Apoptosis; Signal Transduction in Brain Development and Plasticity." 5 Oct. 2006. Northwestern University. 5 Mar. 2007
Smith, Aaron. "Jury: Merck Negligent." CNN Money. 22 Aug. 2005. 24 Mar. 2007
"Toxic Protein That Interferes with Brain Signals May Trigger Onset of Alzheimer's Disease." Science Daily. 28 May 1998. 5 Mar. 2007
RAG Proteins
3-26-07
Paper #2
Final Draft
The RAG Proteins: Ensuring Antibody Diversity
The ability of human immune cells to identify infected cells as harmful is critical to the immune system. Each different kind of pathogen, or infected cell, has its own unique signature that defines it as a danger to the human body and if it goes unrecognized by the lymphocytes it can kill the body. Because of the relative inability of the immune system to generally recognize harm and kill it efficiently, there must be an individual mechanism for identifying the specific threat and eliminating it effectively. It is the job of the antigen receptors on specific lymphocytes to recognize the antigen, or the distinguishing surface protein of pathogens, the only problem is the need for a specific antigen receptor for each antigen. The antigen receptor of the lymphocyte is guaranteed to be able to recognize nearly all antigens because of a process that occurs during DNA replication called V(D)J recombination. This process would not be possible without the RAG, Recombination Activating Genes, proteins that make sure the proper parts of the DNA are replicated. The RAG proteins are the essential machines of V(D)J recombination and make the human immune system as effective as it is.
The antigen receptor of immune cells is the critical part of the immune system that allows it to recognize nearly all threats that enter the body. Once a pathogen enters the body, it should hopefully be recognized by a lymphocyte so it can be destroyed before proliferation. The issue with this is that there is a specific lymphocyte that has the antigen receptor for the unique antigen and an immune response will ensue only if it comes into contact with that specific lymphocyte. Fortunately the immune system has an efficient way of presenting potential pathogens to all lymphocytes so the pathogen can be recognized. However, if the lymphocytes didn't undergo the process of V(D)J recombination during the cells DNA replication the diversity of the antigen receptors would not be great enough to recognize all viable threats.
The antigen receptors of lymphocytes consist of heavy and light chains with both constant and variable regions. These regions are encoded for in the DNA by three different genes; the heavy gene, plus the light chains kappa and lambda. The heavy chain gene has segments that fall into three categories, V, D, and J, while the light chain only uses V and J. In the light chain there are 200 possible kappa gene segments and 124 lambda gene segments; one of these light chains will pair with a heavy change variation. The heavy chain variation comes from there being 51 different possible V gene segments, 25 possible D segments, and 6 possible J segments. There are then nine constant regions that bind with the variable complex composed of one of each V, D, and J segments. All of the different gene segments that could be used to produce the antigen receptor create a diversity of almost 2.5 × 107 possible combinations. The mechanisms involved in making sure V(D)J recombination occurs properly by ensuring that only one of each gene segment is presented includes the RAG proteins.
The most important components of V(D)J recombination are the Recombination Signal Sequences (RSS) and the Recombination Activating Genes (RAG). The RSS appear in the ends of the DNA segments that encode for the various regions of the antigen receptor. These regions of the DNA are recognized by the RAG proteins that then cut the DNA at these points forming a double-stranded break. This double-stranded break is repaired through normal processes, and the cut ends come together to form the DNA that will code for the variable region in the antigen receptor. In the heavy chain, the DJ segments combine and then the complex combines with a V segment, while in light chains the V segment just combines with a J segment.
The RAG proteins, which are RAG-1 and RAG-2, are the mechanisms of V(D)J recombinase that are specific to lymphocyte development. Every species that undergoes V(D)J recombination has the RAG proteins. The RAG proteins function in the development of antigen receptors as follows. First they recognize and align the Recombination Signal Sequences, and it is RAG-1 job specifically to do so. The RAG complex then makes two double-stranded breaks at the 5’ ends of the RSS. The free 3’ group will then create a hairpin structure out of the DNA by attaching itself to the phosphodiester bond on the other strand. It is the job of the RAG complex to hold this new DNA structure together. RAG-1 and RAG-2 then create a single stranded break in the hairpin structure allowing the final result of the recombination of the V, D, and J segments of DNA.
The way RAG proteins work is directly related to their structure. It is known that RAG-1 is responsible for recognizing and binding to the RSS, and it is able to “recruit” the site to bind to using the nonamer-binding-domain (NBD) the RAG protein has. The nonamer is the anchor point for the anchor point for the binding of RAG and RSS complexes. After the RAG protein is anchored to the RSS, the second step of “stabilization” occurs in the presence of RAG-2 which makes the heptamer of the now combined complex available for adding an additional stabilizing site for the interaction. This machine can be compared to a portable saw because it goes right to where it needs to be to perform its function and then cuts through the strands of the DNA. The RAG proteins could also be compared to a vice because after they split the DNA they hold the newly freed end in place until it reconnects with the DNA at a different location, which the proteins lead the end of the DNA to where it is supposed to be like a shepherd.
The RAG proteins have been proven to be essential to a healthy immune system because of the detrimental effects of having a lack of them. Severe Combined Immune Deficiency (SCID) has been proven to be an effect of a lack of RAG proteins. SCID is characterized by the absence of mature B and T lymphocytes necessary for the immune system to function. Mutations in the RAG-1/RAG-2 proteins also result in a condition known as Omenn Syndrome. This is an autosomal recessive form of SCID that has the same effect of being unable to fight infections because of no functioning white blood cells being able to do the job.
In the end it is apparent that the RAG proteins are crucial to the well being of any human. Without the RAG proteins regulating the V(D)J recombination process the immune system would not have mature, diverse lymphocytes available to fight off infection. Without the “portable saw” and “vice-grip” of the RAG proteins the resulting effect would be devastating diseases such as SCID and Omenn Syndrome which significantly lower a person’s quality of life. Without the RAG proteins, human life would not be possible.
Works Cited
“Antigen Receptor Diversity”. http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/AgReceptorDiversity.html#V(D)J_Joining. 9 March 2006.
Posey, Jennifer E, Vicky L Brandt, David B Roth. “Paradigm switching in the germinal center”. Nature Immunology. 2004. 476-477.
Swanson, Patrick C. “Fine Structure and Activity of Discrete RAG-HMG Complexes on V(D)J Recombination Signals”. Molecular Cell Biology. March 2002. 1340-1351.
“RAG-1 and RAG-2”.
http://www.bio.davidson.edu/Courses/Immunology/Students/Spring2003/Beaghan/mfip.html. Davidson College. 2003.
Cancer and Immunotoxins
Mike Epstein
Professor Jed Macosko
Of Molecules and Machines
March 27, 2007
Cancer and Immunotoxins
Cancer is a lethal disease that kills indiscriminately. In addition to claiming hundreds of thousands of American lives each year, cancer also kills millions of impoverished people annually. In 2002 cancer took the lives of 6.7 million people globally. The disease’s future impact on humanity looks even grimmer. It is estimated that in the year 2020, cancer will claim 10.1 million lives. [1]
The developing world contributes greatly to this death toll, considering that eighty-five percent of the global population lives in developing countries. Compared to developed countries, developing countries are greatly lacking in the vital resources needed to treat cancer. Radiotherapy is a common treatment for cancerous tumors; however, developing countries contain only one third of the world’s radiotherapy facilities. Fifteen African states and several Asian states lack even one radiotherapy machine.
It is evident that the world needs a new solution for treating cancer. However in finding a solution, it is important that one understands how cancer works and why it is so deadly.
The term cancer actually refers to over one hundred separate diseases. These diseases are caused by a variety of factors. For instance, certain viruses have been linked to an onset of cancer. These viruses include the human-papillomavirus, which causes genital warts, and the Epstein-Barr virus, which causes mononucleosis. Diseases like AIDS that affect the immune system also can lead to various cancers. [3]
Certain substances called carcinogens increase the risk of getting cancer. Carcinogens like arsenic, asbestos and nickel can cause lung cancer. Tobacco is a common carcinogen which when used results in the development of various cancers, depending upon how it is ingested. Alcohol has been linked to oral cancer, and certain foods have been found to result in cancer. [4]
Furthermore, chromosomal abnormalities can contribute to cancer. Chromosomes are located within the nucleus of a cell, and carry the cell’s genetic information. When chromosomes are defective, either because they contain missing, defective or even rearranged genes, a natural predisposition to develop a cancerous tumor is increased. [5]
Cancer can develop in the healthiest of people because of various genetic mutations they may carry. One such example occurs when there is a genetic mutation in an oncogene. Oncogenes affect the way cells uses energy and multiply. A defective oncogene can contribute to the uncontrolled growth of a tumor. For instance, when the Ras gene (an oncogene) is defective it often produces proteins that cause cells to divide at an accelerated rate. [6]
Finally, mutations in tumor suppressor genes have been found to result in an onset of cancer. Tumor suppressors are supposed to prevent tumors from forming. However, when mutated these suppressors allow cells with abnormal DNA to survive and multiply. [7]
Looking at cancer’s long list of known causes, it is easy to see how one in two men and one in three women will develop cancer in their lifetimes. [8] The development of cancer starts with a basic malignant cell. Malignant cells are dangerous because they divide at a pace that is much more rapid than the pace of normal cells. These cells divide rapidly because they carry damaged genes. As the cells keep dividing, they cluster together to form a malignant tumor. [9]
Tumors cause great destruction to the body. First, they put pressure on nearby tissues and organs. The tumors can invade these organs directly through a process called direct extension, and they often damage and even disable organs. Furthermore, malignant tumors make invaded organs and tissues more susceptible to infection. Finally, tumors can destroy nearby tissues by releasing harmful substances. [10]
Tumors can thrive throughout the body. They can spread from their origin through a process called metastasis. Metastasis occurs when a tumor releases millions of malignant cells into the nearby bloodstream. Fortunately, most of these cells are killed by the immune system, or from the trauma of traveling through the walls’ of blood vessels. However, surviving malignant cells can bind to the lining of these walls. As more and more cells bind to a new location elsewhere in the body, a new tumor develops. [11]
It is clear that malignant tumors are the main threat that cancer presents to the body. In treating cancer, it is essential that these tumors be eradicated. Fortunately, drugs called immunotoxins are created for this very purpose. The job of an immunotoxin is to seek and destroy malignant tumors. One can think of an immunotoxin as a “nanoscale scalpel,” because of its ability to specifically target and kill dangerous tumors. [12]
Immunotoxins are chimeric by nature. They are composed of an antibody, which seeks out cancerous tumors, and a toxin, which kills the tumors. These two components are cloned together through recombinant DNA techniques. [13]
The antibody is an essential part of an immunotoxin. Malignant cells have a different class of proteins that are involved in cell-to-cell interaction and adhesion. Certain antibodies have the ability to bind to these proteins. The antibodies that can bind to malignant cells are determined, and cloned to a toxin of choice. [14]
Toxins alone are merely health hazards. A toxin targets indiscriminately, killing normal and malignant cells alike, causing the body great damage internally. However, when attached to the right antibody, toxins become biological tools that have the potential to destroy whole tumors. Essentially, they are “suicide nanorobots.” After binding to a cancerous cell, immunotoxins will enter and destroy it. A toxin unleashed inside a cell jumps from one molecule to the next, killing it with ease. After destroying the cell, the immunotoxin simply self-destructs. [15]
Immunotoxins are a promising treatment for cancer patients. In December, 2006, the National Cancer Institute revealed that the immunotoxin BL22 caused complete remission of hairy-cell leukemia after just three doses in half of the patients tested in a clinical trail. The BL22 immunotoxin is composed of the PE38 toxin and an antibody that binds to the receptor CD22, which is found on hairy-cell leukemia cells. The PE38 toxin is derived from a toxin produced by bacteria. It has the ability to kill human cells by blocking their ability to make new proteins. [16]
While the BL22 immunotoxin help sufferers of hairy-cell leukemia achieve remission, it does not yet have the ability to help patients with solid tumors. Leukemia causes a person to have a poor immune system; therefore patients cannot create an immune response to the PE38 toxin, and it can target cancerous cells before being struck down by the immune system. However, in patients with solid tumors who also have stronger immune systems, the PE38 is destroyed before it can make its way to these tumors. [17]
Currently researchers are cleverly working around this problem. After testing in mice which antibodies specifically reacted to the toxin, researchers have already identified sites on the PE38 that stimulate a response from the immune system. The researchers are now working on creating a strand of the PE38 toxin that lacks the amino acids that provoke a reaction from these antibodies. In creating the new and improved PE38, researchers will be able to make an immunotoxin with the potential to destroy solid tumors. [18]
Cancer ends life in a painful, torturous manner; it is difficult to understand how it can start through a single malignant cell. Nevertheless, it does and in doing so kills millions of people around the world every year. Cancer is expected to attack fifteen million people in the single year of 2020. The developing world faces nine million of these new cases, and will lack the ability to treat a majority of those afflicted. [19] Radiotherapy is costly and expensive, and often times ineffective in killing off malignant tumors; the world needs to rely on a better cancer treatment. As displayed by the BL22, immunotoxins have the potential to be the wonder drug that the world so badly needs in eradicating cancer. Immunotoxins can bring an end to malignant tumors, to cancer, and to painful deaths that millions worldwide have no alternative but to suffer through.
[1]: "Statistics for 2006." ACS. 2007. ACS. 2 Mar. 2007
[2]: "Developing World Faces Cancer Crisis." BBC. 26 June 2003. 3 Mar. 2007
[3-7]: Gordon, Jerry. "How Cancer Works." Howstuffworks. 4 Mar. 2007
[8]: "Statistics for 2006." ACS. 2007. ACS. 2 Mar. 2007
[9-11]: Gordon, Jerry. "How Cancer Works." Howstuffworks. 4 Mar. 2007
[12-15]: Goodsell, David S. Bionanotechnology: Lessons From Nature.
[16-18]: Pastan, I, and R Hassan. "NCI Researchers Develop Modified Immunotoxin for Cancer Therapy in Mouse Study." NCI. 12 Apr. 2006. 5 Mar. 2007
[19]: "Cancer Menace on the Rise." BBC. 31 Aug. 2001. 3 Mar. 2007